6935 Stock Overview
Produces and sells vitamin B1 active pharmaceutical ingredients in Taiwan, Japan, Spain, Europe, etc. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 1/6 |
Prince Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$21.95 |
| 52 Week High | NT$36.55 |
| 52 Week Low | NT$20.75 |
| Beta | 0 |
| 11 Month Change | -4.77% |
| 3 Month Change | -6.40% |
| 1 Year Change | -36.93% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -59.12% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6935 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -0.7% | 0.7% | -1.4% |
| 1Y | -36.9% | 6.8% | 26.5% |
Return vs Industry: 6935 underperformed the TW Pharmaceuticals industry which returned 7.8% over the past year.
Return vs Market: 6935 underperformed the TW Market which returned 28.7% over the past year.
Price Volatility
| 6935 volatility | |
|---|---|
| 6935 Average Weekly Movement | 6.3% |
| Pharmaceuticals Industry Average Movement | 3.5% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 6935 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6935's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1962 | 210 | Da Li | www.prince-pharm.com.tw |
Prince Pharmaceutical Co., Ltd. produces and sells vitamin B1 active pharmaceutical ingredients in Taiwan, Japan, Spain, Europe, etc. The company was founded in 1962 and is headquartered in Yunlin, Taiwan.
Prince Pharmaceutical Co., Ltd. Fundamentals Summary
| 6935 fundamental statistics | |
|---|---|
| Market cap | NT$803.48m |
| Earnings (TTM) | -NT$15.23m |
| Revenue (TTM) | NT$737.13m |
1.1x
P/S Ratio-52.7x
P/E RatioIs 6935 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6935 income statement (TTM) | |
|---|---|
| Revenue | NT$737.13m |
| Cost of Revenue | NT$614.55m |
| Gross Profit | NT$122.58m |
| Other Expenses | NT$137.81m |
| Earnings | -NT$15.23m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.42 |
| Gross Margin | 16.63% |
| Net Profit Margin | -2.07% |
| Debt/Equity Ratio | 46.8% |
How did 6935 perform over the long term?
See historical performance and comparison